Innovative pharmaceutical industry reached a turning point in performance, with 17 listed companies seeing a year-on-year net profit growth of over 100%.

Data shows that the innovative pharmaceutical industry will see a turning point in performance in 2025, with 17 listed companies including Tonghua Dongbao, Walvax Biotechnology, and Nanmo Biotechnology experiencing a net profit growth of over 100% year-on-year. Among them, Tonghua Dongbao achieved a net profit of 1.219 billion yuan in 2025, an increase of 3005.63% year-on-year. The net profit growth of Walvax Biotechnology, Nanmo Biotechnology, Sanescance Health, and Zhaoyan Pharmaceuticals all exceeded 300%, while Liaoning Chengda and Shengnuo Biology also achieved growth rates of over 200%. In terms of stock price performance, most companies' stock prices are positively correlated with performance growth. Tonghua Dongbao has risen by 12.97% year-to-date, Rongchang Biotechnology has risen by over 60%, and Pharmaron has risen by over 20.86%. However, some companies have shown poor stock price performance, such as Walvax Biotechnology, which has fallen by 20.84% year-to-date, and BeiGene has fallen by 12.58%.